{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:47:35Z","timestamp":1764251255870,"version":"build-2065373602"},"reference-count":98,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001219","name":"Lymphoma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.3816\/clml.2010.n.066","type":"journal-article","created":{"date-parts":[[2010,11,10]],"date-time":"2010-11-10T23:44:49Z","timestamp":1289432689000},"page":"336-346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Management of Mantle Cell Lymphoma: Key Challenges and Next Steps"],"prefix":"10.3816","volume":"10","author":[{"given":"Michael E.","family":"Williams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Winter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabeeha","family":"Muneer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLML.2010.n.066_bib1","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.3816\/CLML.2010.n.066_bib2","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V88.4.1177.bloodjournal8841177","article-title":"Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization","volume":"88","author":"Vaandrager","year":"1996","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib3","first-page":"1833","article-title":"Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma","volume":"10","author":"de Boer","year":"1995","journal-title":"Oncogene"},{"key":"10.3816\/CLML.2010.n.066_bib4","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1182\/blood.V84.8.2726.2726","article-title":"PRAD-1\/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma","volume":"84","author":"Bosch","year":"1994","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib5","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","article-title":"Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts","volume":"3","author":"Fry","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.3816\/CLML.2010.n.066_bib6","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1182\/blood-2006-04-016634","article-title":"Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity","volume":"108","author":"Marzec","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib7","doi-asserted-by":"crossref","unstructured":"Niesvizky R, Ely S, Jayabalan D, et al. A Phase I trial of PD 0332991, a novel, orally-bioavailable cdk4\/6-specific inhibitor administered in combination with bortezomib and dexamethasone to patients with relapsed and refractory multiple myeloma. Presented at: the 51st American Society of Hematology Annual Meeting and Exposition; December 5\u20138, 2009; New Orleans, LA. Abstract 1877.","DOI":"10.1182\/blood.V114.22.1877.1877"},{"key":"10.3816\/CLML.2010.n.066_bib8","doi-asserted-by":"crossref","unstructured":"Buglio D, Palakurthi S, Byth KF, et al. The Tak-1 inhibitor AZ-Tak1 inhibits XIAP, activates caspase-9, and induces apoptosis in mantle cell lymphoma. Presented at: the 51st American Society of Hematology Annual Meeting and Exposition; December 5\u20138, 2009; New Orleans, LA. Abstract 1692.","DOI":"10.1182\/blood.V114.22.1692.1692"},{"issue":"15 suppl","key":"10.3816\/CLML.2010.n.066_bib9","first-page":"129s","article-title":"Treatment of relapsed or refractory non-Hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study","volume":"26","author":"Younes","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib10","doi-asserted-by":"crossref","unstructured":"Younes A, Fanale M, McLaughlin P, et al. Phase-I study of the novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: evidence of clinical and biologic activity. Presented at: the 51st American Society of Hematology Annual Meeting and Exposition; December 5\u20138, 2009; New Orleans, LA. Abstract 588.","DOI":"10.1182\/blood.V114.22.588.588"},{"key":"10.3816\/CLML.2010.n.066_bib11","doi-asserted-by":"crossref","unstructured":"Younes A, Copeland AR, Romaguera J, et al. Clinical and biologic activity of the heat shock protein-90 (HSP-90) inhibitor 17-AAG in patients with relapsed lymphoma. Presented at: the 51st American Society of Hematology Annual Meeting and Exposition; December 5\u20138, 2009; New Orleans, LA. Abstract 3744.","DOI":"10.1182\/blood.V114.22.3744.3744"},{"key":"10.3816\/CLML.2010.n.066_bib12","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood.V114.22.1708.1708","article-title":"Satefy and tolerability of conatumumab in combination with bortezomib or vorinostat in patients with relapsed or refractory lymphoma","volume":"114","author":"Younes","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib14","doi-asserted-by":"crossref","unstructured":"Opat S, Farinha P, Boyle M, et al. The percentage of cytotoxic T-Cells in mantle cell lymphoma (MCL) biopsies predicts response to rituximab. Presented at: the 51st American Society of Hematology Annual Meeting and Exposition; December 5\u20138, 2009; New Orleans, LA. Abstract 2923.","DOI":"10.1182\/blood.V114.22.2923.2923"},{"key":"10.3816\/CLML.2010.n.066_bib15","doi-asserted-by":"crossref","unstructured":"Farinha P, Opat S, Boyle M, et al. Number of lymphoma-associated-macrophages (LAM) is an independent predictor of survival in patients with mantle cell lymphoma (MCL). Presented at: the 51st American Society of Hematology Annual Meeting and Exposition; December 5\u20138, 2009; New Orleans, LA. Abstract 3944.","DOI":"10.1182\/blood.V114.22.3944.3944"},{"key":"10.3816\/CLML.2010.n.066_bib16","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood-2005-04-1565","article-title":"Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)","volume":"106","author":"Farinha","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib17","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.066_bib18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrc1256","article-title":"Tumour-educated macrophages promote tumour progression and metastasis","volume":"4","author":"Pollard","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.3816\/CLML.2010.n.066_bib19","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1309\/AJCPV8LN5ENMZOVY","article-title":"Immunophenotypic variations in mantle cell lymphoma","volume":"132","author":"Gao","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.3816\/CLML.2010.n.066_bib20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z","article-title":"Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors","volume":"82","author":"Bosch","year":"1998","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.n.066_bib21","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood.V89.4.1421","article-title":"Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones","volume":"89","author":"Ott","year":"1997","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib22","first-page":"4365","article-title":"Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants","volume":"93","author":"Be\u00e0","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib23","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib24","doi-asserted-by":"crossref","unstructured":"Smith SD, Hsi E, Bolwell BJ, et al. Validation of the Mantle Cell Lymphoma Prognostic Index (MIPI): a valuable tool for risk stratification in mantle cell lymphoma. Presented at: the 51st American Society of Hematology Annual Meeting and Exposition; December 5\u20138, 2009; New Orleans, LA. Abstract 2703.","DOI":"10.1182\/blood.V114.22.2703.2703"},{"key":"10.3816\/CLML.2010.n.066_bib25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"10.3816\/CLML.2010.n.066_bib26","doi-asserted-by":"crossref","DOI":"10.1007\/s12308-009-0036-x","article-title":"Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network","author":"Klapper","year":"2009","journal-title":"J Hematop"},{"key":"10.3816\/CLML.2010.n.066_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/annonc\/mdp495","article-title":"Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma","volume":"21","author":"Schaffel","year":"2010","journal-title":"Ann Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib28","doi-asserted-by":"crossref","unstructured":"Hoster E, Metzner B, Forstpointner R, et al. Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma. Presented at: the 51st American Society of Hematology Annual Meeting and Exposition; December 5\u20138, 2009; New Orleans, LA. Abstract 880.","DOI":"10.1182\/blood.V114.22.880.880"},{"key":"10.3816\/CLML.2010.n.066_bib29","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib30","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib31","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","article-title":"Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma","volume":"27","author":"Andersen","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib32","doi-asserted-by":"crossref","unstructured":"Dreyling M, Hiddemann W. Current treatment standards and emerging strategies in mantle cell lymphoma. In: American Society of Hematology Education Program Book, Washington, DC: American Society of Hematology (ASH); 2009:542\u201354.","DOI":"10.1182\/asheducation-2009.1.542"},{"key":"10.3816\/CLML.2010.n.066_bib33","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.1998.16.5.1922","article-title":"Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group","volume":"16","author":"Hiddemann","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib34","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib35","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib36","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib37","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.066_bib38","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.387.387","article-title":"A Multi Center Trial of hyperCVAD+Rituxan in Patients with Newly Diagnosed Mantle Cell Lymphoma","volume":"110","author":"Epner","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib39","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/annonc\/mdl127","article-title":"Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network","volume":"17","author":"Kahl","year":"2006","journal-title":"Ann Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib40","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/annonc\/mdn045","article-title":"Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies","volume":"19","author":"Martin","year":"2008","journal-title":"Ann Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib41","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib42","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.n.066_bib43","doi-asserted-by":"crossref","unstructured":"Rummel MJ, Nierderle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and cr rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Presented at: the 51st American Society of Hematology Annual Meeting and Exposition; December 5\u20138, 2009; New Orleans, LA. Abstract 405.","DOI":"10.1182\/blood.V114.22.405.405"},{"issue":"suppl 4","key":"10.3816\/CLML.2010.n.066_bib44","first-page":"300","article-title":"European Mantle Cell Lymphoma Network: An Update on Current First Line Trials","volume":"19","author":"Dreyling","year":"2008","journal-title":"Ann Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib45","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","article-title":"The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)","volume":"115","author":"Geisler","year":"2010","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib46","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib47","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood.V114.22.3327.3327","article-title":"Prognostic factors on outcome of mantle cell lymphoma patients relapsing after autologous hematopoietic stem cell transplantation","volume":"114","author":"Budde","year":"2009","journal-title":"Blood"},{"issue":"18 suppl","key":"10.3816\/CLML.2010.n.066_bib48","first-page":"424s","article-title":"Mantle cell lymphoma (MCL): Induction therapy with HyperCVAD\/High-dose methotrexate and cytarabine (M-C) (\u00b1 rituximab) improves results of autologous stem cell transplant in first remission","volume":"24","author":"Vose","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib49","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2141.2008.07498.x","article-title":"High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients","volume":"144","author":"Van't Veer","year":"2009","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.066_bib50","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909","volume":"27","author":"Damon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood.V114.22.403.403","volume":"114","author":"LaCasce","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib52","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib53","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","article-title":"Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study","volume":"16","author":"Lefrere","year":"2002","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.066_bib55","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1182\/blood.V112.11.2147.2147","article-title":"Sustained graft-versus-lymphoma effect among patients (pts) with mantle cell lymphoma (MCL) given nonmyeloablative allogeneic hematopoietic cell transplantation (HCT)","volume":"112","author":"Sorror","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib56","first-page":"174","article-title":"Identification of prognostic factors predicting the outcome of reduced intensity allogeneic stem cell transplantation in mantle cell lymphoma. an analysis from the lymphoma working party of the EBMT","volume":"112","author":"Robinson","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib57","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood.V114.22.3366.3366","article-title":"First line allogeneic stem cell transplantation in mantle cell lymphoma (MCL)","volume":"114","author":"Lachance","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib58","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdh425","article-title":"Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study","volume":"15","author":"Brugger","year":"2004","journal-title":"Ann Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib59","doi-asserted-by":"crossref","first-page":"121a","DOI":"10.1182\/blood.V110.11.389.389","article-title":"Phase II study of R-CHOP followed by 90Y-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative Oncology Group Study E1499","volume":"110","author":"Smith","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib60","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1200\/JCO.2004.00.9217","article-title":"Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"10.3816\/CLML.2010.n.066_bib61","first-page":"54","article-title":"Sequential rituximab with tositumomab\/I131 tositumomab followed by CHOP chemotherapy is a safe and highly effective regimen","volume":"16","author":"Zelenetz","year":"2005","journal-title":"Ann Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib62","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood.V112.11.3053.3053","article-title":"A Phase II trial of induction plus maintenance rituximab and bortezomib in patients with relapsed\/refractory mantle cell (MCL) and follicular (FL) non-Hodgkin's lymphoma","volume":"112","author":"Blum","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib64","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/leu.2009.173","article-title":"Proteasome inhibitors in the treatment of multiple myeloma","volume":"23","author":"Shah","year":"2009","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.066_bib65","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib66","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.leukres.2006.03.005","article-title":"Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells","volume":"30","author":"Smolewski","year":"2006","journal-title":"Leuk Res"},{"key":"10.3816\/CLML.2010.n.066_bib67","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00126839-200708010-00001","article-title":"Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors","volume":"8","author":"Cheriyath","year":"2007","journal-title":"Drugs R D"},{"key":"10.3816\/CLML.2010.n.066_bib69","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","article-title":"Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein","volume":"112","author":"Oerlemans","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib70","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res"},{"key":"10.3816\/CLML.2010.n.066_bib71","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":"A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies","volume":"15","author":"O'Connor","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.066_bib72","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood.V114.22.430.430","article-title":"Carfilzomib (CFZ), a novel proteasome inhibitor for relapsed or refractory multiple myeloma, is associated with minimal peripheral neuropathic effects","volume":"114","author":"Vij","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib73","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood.V114.22.303.303","article-title":"PX-171-004, an ongoing open-label, phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM); updated results from the bortezomib-treated cohort","volume":"114","author":"Siegel","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib74","first-page":"127","article-title":"Updated results of bortezomib-naive patients in PX-171-004, an ongoing open-label, phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM)","volume":"114","author":"Wang","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib75","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"key":"10.3816\/CLML.2010.n.066_bib76","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1182\/blood.V114.22.431.431","article-title":"Phase 1 clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed\/refractory multiple myeloma (MM)","volume":"114","author":"Richardson","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib77","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","article-title":"Bendamustine: rebirth of an old drug","volume":"27","author":"Cheson","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib78","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","article-title":"Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study","volume":"116","author":"Kahl","year":"2009","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.n.066_bib79","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib80","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib82","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1182\/blood.V114.22.924.924","article-title":"Bendamustine, bortezomib and rituximab in patients (pts) relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma (NHL): a multicenter phase II clinical trial","volume":"114","author":"Friedberg","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib83","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies","volume":"2","author":"Kotla","year":"2009","journal-title":"J Hematol Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib84","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.066_bib85","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.066_bib86","first-page":"271","article-title":"Lenalidomide in myelodysplastic syndromes","volume":"6","author":"List","year":"2008","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib87","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood.V114.22.1676.1676","article-title":"Durable responses after lenalidomide oral monotherapy in patients with relapsed or refractory (R\/R) aggressive non-Hodgkins lymphoma (a-NHL): results from an international phase 2 study (CC-5013-NHL-003)","volume":"114","author":"Witzig","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib88","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood.V112.11.1560.1560","article-title":"The efficacy and safety of lenalidomide oral monotherapy in patients with mantle cell lymphoma previously treated with bortezomib: pooled data from two phase ii studies (NHL-002 and NHL-003)","volume":"112","author":"Reeder","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib89","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood.V114.22.1713.1713","article-title":"Salvage treatment with lenalidomide and dexamethasone in patients with relapsed refractory mantle cell lymphoma","volume":"114","author":"Zaja","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib90","first-page":"1064","article-title":"A Phase I\/II study of lenalidomide in combination with rituximab in relapsed\/refractory mantle cell lymphoma","volume":"114","author":"Wang","year":"2009","journal-title":"Blood"},{"issue":"15 suppl","key":"10.3816\/CLML.2010.n.066_bib91","first-page":"599s","article-title":"A phase II trial of bortezomib plus lenalidomide for relapsed\/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis","volume":"28","author":"Morrison","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib94","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.066_bib95","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","article-title":"A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer","volume":"12","author":"Hidalgo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.066_bib96","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib97","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.n.066_bib98","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib99","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood.V114.22.1665.1665","article-title":"A phase II study of temsirolimus (CCI-779) in combination with rituximab in patients with relapsed or refractory mantle cell lymphoma","volume":"114","author":"Ansell","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib101","doi-asserted-by":"crossref","first-page":"44a","DOI":"10.1182\/blood.V110.11.121.121","article-title":"A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed aggressive non-Hodgkin lymphoma (NHL)","volume":"110","author":"Reeder","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.066_bib102","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1158\/1078-0432.CCR-07-1372","article-title":"A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies","volume":"14","author":"Rizzieri","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.066_bib103","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2008.07353.x","article-title":"Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma","volume":"143","author":"Pro","year":"2008","journal-title":"Br J Haematol"},{"issue":"15 suppl","key":"10.3816\/CLML.2010.n.066_bib104","first-page":"456s","article-title":"A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies","volume":"26","author":"Wilson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.066_bib105","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.4987.4987","article-title":"Pre-clinical evaluation of a novel purine analogue 8-nh2-adenosine in mantle cell lymphoma indicates efficacy via alterations in RNA\/DNA synthesis and cellular bioenergetics","volume":"112","author":"Shanmugam","year":"2008","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011701999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011701999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:23:28Z","timestamp":1761870208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011701999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":98,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S2152265011701999"],"URL":"https:\/\/doi.org\/10.3816\/clml.2010.n.066","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Mantle Cell Lymphoma: Key Challenges and Next Steps","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLML.2010.n.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}